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Abstract 
Background: Atopic dermatitis (AD) is a chronic inflammatory disease caused by the complex interaction of genetic, 
immune and environmental factors. There have many recent discoveries involving the genetic and epigenetic studies 
of AD.
Methods: A retrospective PubMed search was carried out from June 2009 to June 2016 using the terms “atopic 
dermatitis”, “association”, “eczema”, “gene”, “polymorphism”, “mutation”, “variant”, “genome wide association study”, “micro-
array” “gene profiling”, “RNA sequencing”, “epigenetics” and “microRNA”. A total of 132 publications in English were 
identified.
Results: To elucidate the genetic factors for AD pathogenesis, candidate gene association studies, genome-wide 
association studies (GWAS) and transcriptomic profiling assays have been performed in this period. Epigenetic mecha-
nisms for AD development, including genomic DNA modification and microRNA posttranscriptional regulation, have 
been explored. To date, candidate gene association studies indicate that filaggrin (FLG) null gene mutations are the 
most significant known risk factor for AD, and genes in the type 2 T helper lymphocyte (Th2) signaling pathways are 
the second replicated genetic risk factor for AD. GWAS studies identified 34 risk loci for AD, these loci also suggest that 
genes in immune responses and epidermal skin barrier functions are associated with AD. Additionally, gene profiling 
assays demonstrated AD is associated with decreased gene expression of epidermal differentiation complex genes 
and elevated Th2 and Th17 genes. Hypomethylation of TSLP and FCER1G in AD were reported; and miR-155, which 
target the immune suppressor CTLA-4, was found to be significantly over-expressed in infiltrating T cells in AD skin 
lesions.
Conclusions: The results suggest that two major biologic pathways are responsible for AD etiology: skin epithelial 
function and innate/adaptive immune responses. The dysfunctional epidermal barrier and immune responses recip-
rocally affect each other, and thereby drive development of AD.
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Background
Atopic dermatitis (AD) is the most common skin dis-
ease worldwide, affecting up to 30 % of children and 3 % 
of adults [1]. Together with food allergy, allergic rhinitis 
and atopic asthma, AD belongs to the atopic group of 
disorders with common characteristics of allergen sen-
sitization, epithelial barrier abnormalities and Type 2 
immune responses [2]. A number of familial studies and 
twin studies have demonstrated that AD is a highly her-
itable disease [3–9]. The rapid increase in prevalence of 
AD has been attributed to changes in life style and the 
environment. A comprehensive review by Barnes sum-
marized genetic studies on AD before June of 2009 [10]. 
In her review, outcomes of 5 linkage studies and 111 
targeted gene association studies were analyzed. Look-
ing retrospectively, the year of 2009 was a time point for 
transition to a new era in which genome-wide associa-
tion studies (GWAS) emerged as a popular approach to 
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elucidate the genetic susceptibility of human complex 
diseases such as AD. Concomitantly, epigenetic altera-
tions in response to environmental exposures opened a 
novel area for researchers to explore AD etiology. After 
June 2009, targeted gene association studies were still 
actively used, however, traditional genetic linkage stud-
ies for AD had been substituted by GWAS studies with 
large scale sample sizes in different populations. During 
the last 5  years, next-generation sequencing technolo-
gies have been increasingly used in AD research: two 
whole exome analyses were reported for the purpose of 
finding rare genetic variants in coding sequences of the 
AD genome; and high-throughput gene expression pro-
filing assays such as RNA-sequencing technology were 
performed on skin biopsy specimens from AD patients. 
Although several reviews on the topic of AD genetics 
and epigenetics have been published since 2009 [11–13], 
more than 30 new studies have been reported since Janu-
ary, 2015. In this article, we summarize genetics and epi-
genetics studies on AD between June of 2009 and June of 
2016. Studies from both adults and children with differ-
ent ethnicities are included in this review. Additionally, a 
few studies of genome wide comparative analyses of AD 




We performed the literature search in PubMed data-
base using the terms “atopic dermatitis” or ‘eczema” and 
“association”, or “gene”, or “polymorphism”, or “muta-
tion”, or “variant”, or “genome wide association study”, or 
“microarray”, or “gene profiling”, or “RNA-sequencing”, 
or “epigenetics”, or “microRNA”, from June 2009 to pre-
sent. Abstracts of the PubMed results were reviewed to 
identify any target gene association case–control stud-
ies, GWAS studies, gene profiling studies and epigenet-
ics studies including both DNA methylation studies and 
microRNA studies of AD. Articles published in non-Eng-
lish languages were excluded.
This review included all results obtained from children 
and adults in all ethnicities. Comparative studies on “AD” 
and “AD plus asthma”, “AD” and “atopic march”, “AD” and 
“psoriasis” were included.
Results
Candidate gene association studies
Candidate gene association studies have focused on the 
skin epidermal differentiation complex genes and Type 
2 immune responses based on our understanding of the 
pathophysiology of AD. The review by Barnes, in 2010, 
had examined 81 genes that had been studied prior to 
June 2009 [10]. Using the same strategy of literature 
research as Barnes, we identified 92 published studies 
on candidate gene association studies in AD (Additional 
file 1: Table S1, Additional file 2: Reference). Among these 
92 studies, 65 genes were investigated, more than half of 
which had at least 1 positive association. To date, FLG 
null mutation is the most replicated AD gene association. 
Genes in the Th2 signaling pathway are the second cat-
egory that has been replicated by multiple independent 
studies. Beside IL-4, IL-13, IL-4RA, IL13RA1, IL-13RA2 
and STAT6, newly tested genes in this category are 
thymic stromal lymphopoietin (TSLP), its receptors IL-7R 
and TSLPR [14], and IL-31 [15]. In the skin barrier gene 
category, LAMA3 [16], TMEM79, filaggrin-2(FLG2) [17] 
and Late Cornified Envelope-like Proline-rich 1 (LELP1) 
[18] were identified to be associated with AD. The vita-
min D signaling pathway is a novel pathway that has been 
explored in AD. In this regard, vitamin D receptor (VDR) 
polymorphisms and CYD27A1 were found to be associ-
ated with AD severity [19–21]. Additionally, IL10, IL6, 
TNFA and IL-1 family members were studied in this time 
frame. A few candidates from GWAS were also tested. 
Genes studied are summarized in Fig.  1 which include 
the analyses from Barnes’ review.
Genome‑wide association studies (GWAS)
Candidate gene association studies are extremely limited 
in scope because the selection of candidates is often from 
known genes with selection biases from the investigators. 
Thus, this approach usually does not identify novel genes 
or novel pathophysiological pathways. To date, of the 
estimated 30,000 human genes, only a very small portion 
of the transcriptome, have been carefully investigated. 
A hypothesis-free approach can significantly decrease 
biases and lead to identification of novel pathophysiol-
ogy pathways for AD. Single nucleotide polymorphisms 
(SNP) are the most common class of genetic variations in 
humans. The haplotype structure of the human genome 
suggests that a set of 1 million SNP can capture approxi-
mately 90  % of genetic variation in the population. The 
data from the Hapmap project and development of dense 
genotyping chips allow GWAS assays to be effectively 
conducted on a large number of samples. Therefore, 
GWAS became a powerful method to comprehensively 
investigate associations between common SNP and com-
plex diseases [22]. Using the key words “genome wide 
association study” and “atopic dermatitis” to search the 
Pubmed database, a total of 13 articles were published 
since 2009, 9 articles focused exclusively on AD, 4 other 
articles did genome-wide comparative analysis of AD 
with asthma/atopic march and psoriasis.
The first GWAS study of AD was published in May 
2009 by Esparza-Gordillo et  al. It was performed on a 
German cohort of 939 cases and 975 controls as well as 
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275 complete nuclear families with two affected siblings 
[23]. This study replicated FLG locus as an AD predis-
posing factor and identified a novel susceptibility region 
at chromosome 11q13.5 located 38  kb down-stream of 
C11orf30. Two year later in 2011, Sun et  al. reported a 
GWAS study on Chinese Han population, FLG region 
was once more validated in Chinese population and two 
novel loci of 5q22.1 and 20q13.33 were identified. These 
two loci were validated using 1806 cases and 3256 con-
trols from Germany [24]. Interestingly, the TSLP gene 
is located about 300  kb down-stream of the associated 
region of 5q22.1. In the same year of 2011, Paternoster 
et al. [25] published a meta-analysis of GWAS on Euro-
pean ancestry, in which they identified three more new 
risk loci for AD (11q31.1, 19p13.2, 5q31). In addition, 
this study reported a significant genome-wide associa-
tion signal within the cytokine cluster on 5q31.1 due to 
two distinct signals, one centered on RAD50/IL13 and 
the other on IL4/KIF3A. In 2012, Hirota et  al. reported 
GWAS study findings in the Japanese population, this 
study added eight other novel susceptibility loci, includ-
ing the major histocompatibility complex (MHC) region 
on chromosome 6p21 and the IL1RL1–IL18R1–IL18RAP 
locus on chromosome 2q12 [26]. In 2013, Ellinghaus 
et al. reported the densely genotyped results of 2425 Ger-
man cases and 5449 controls using an Immunochip array 
[27], followed by replication in 7196 cases and 15,480 
controls from Germany, Ireland, Japan, and China. Four 
additional novel susceptibility loci for AD were identified 
(4q27 IL2/IL21, 11p13 PRR5L, 16p13.13 CLEC16A/DEXI, 
17q21.32 ZNF652). Adjacent genes to these loci include 
TRAF6, RAG1, RAG2, SOCS1 and NGFR [27]. Addition-
ally, Esparza-Gordillo et  al. analyzed data in the public 
repository and validated selected markers in three dif-
ferent sets of cases and controls, and identified 4 SNPs, 
rs2040704 (RAD50), rs10903122 (RUNX3), rs2292239 
(ERBB3) and rs2228145 (IL6R), as new susceptibility 
genes for AD. The authors further validated that the IL6R 
rs2228145 (C) genotype is associated with increased sol-
uble IL-6R plasma levels in AD and persistent AD status 
using two independent population-based cohort [28].
In 2015, 3 more reports involving GWAS study and AD 
were published. Schaarschmidt et  al. analyzed imputed 
SNP data from previous GWAS studies, followed by 
validation with additional case and control cohorts. This 
study validated 19 of previously established AD genetic 
risk loci and identified two new susceptibility loci (2q24.3 
and 9p21.3) with genome-wide significance in German 




























Genes in red mean new studies or increased replicaon of studies.
*Replicaon sought but failed.
Genes tested but negaves associaons: C3, CCR4, CMA1, DEFA4, DEFA5, DEFA6, 
GPRA, IFNG, IL13RA, IL1B,IL1RN, IL6, IL8, IL8RA, IL8RB, IRAKM, KLK7, LMP2, LMP7, 
MCP1, MHC2TA, MIP1A, NALP1, NALP12, NALP3, NGFB, NPSR1, PDYN, SETDB2, 
STAT6, TAP1, TARC, TIM3, TLR6, TNFA, IL1A, IL1B, IL1RA, LCE3B-LCE3C, LAMB3, 

























































Fig. 1 Genes associated with AD in at least 1 publication. Genes are grouped based on the reported positive association studies (see Additional 
file 1: Table S1 in the supplemental materials for a complete summary of 91 published studies). The Y-axis indicates the number of genes. The X-axis 
indicates the corresponding number of positive association reported
Page 4 of 14Bin and Leung  Allergy Asthma Clin Immunol  (2016) 12:52 
population [29]. Kim et  al. conducted the first GWAS 
assay in Korean population which was aimed to identify 
genetic biomarkers for moderate-to-severe AD in chil-
dren. Since the discovery cohort of this study only con-
tained 246 AD cases, the results from this report are not 
discussed in this review [30]. To note, the AD GWAS 
study with the best statistic power so far is conducted by 
Paternoster et  al. who led an international collaborated 
study. This study included 21,000 cases and 95,000 con-
trols with multi-ancestry in the discovery cohort, the 
results were replicated in 32,059 cases and 228,628 con-
trols, 15,539,996 variants with minor allele frequency 
(MAF) ≥ 1 % were analyzed [31]. This study had not only 
replicated 16 AD risk loci identified by previous GWAS 
studies, but also identified 11 more new risk loci for AD. 
The new loci include candidate genes of CD207 (lan-
gerin), PPP2R3C, IL-7R, STAT3 and ZBTB10, with known 
function in the regulation of innate host defenses and 
T cell function [32–36]. Taken together, these 8 GWAS 
assays and meta-analyses reported 34 AD risk loci as 
listed in Table 1.
Children with AD often develop asthma and other 
allergic conditions later in life. This phenomenon is 
termed “the atopic march” [37]. Identification of genetic 
risk factors for the atopic march is important for the 
development of asthma prevention strategies. Weidinger 
et  al. conducted a GWAS study to specifically examine 
the genetic differences between the AD endophenotypes 
“AD plus asthma” and “AD no asthma” [38]. In this study, 
1563 cases of children-onset AD with known asthma sta-
tus and 4054 European controls were genotyped as dis-
covery cohort. Association variants were further assessed 
for a replication cohort including 2286 European cases 
and 3160 European controls. The results found that FLG 
locus, 5q31 between RAD 50 and IL-13 locus, 6p21 MHC 
locus and 11q13.5 locus were associated with the co-
morbidity of AD and asthma. Using more stringent cri-
teria of inclusion for the atopic march cases (eczema up 
to the age of 3  years and asthma up to age of 16  years) 
as compared to the study of Weidinger et al., Marenholz 
et  al. conducted a meta-analysis to search for genetic 
markers of the atopic march in European descents [39]. 
This study validated the results of the Weidinger et  al. 
report. Additionally, two novel loci (6p12.3/EFHC1 and 
12q21.3/SLC6A15) for the atopic march were reported. 
Importantly, both studies demonstrated a strong con-
tribution of AD risk genes to subsequent asthma occur-
rence in the atopic march, supporting the epidemiology 
observation that infantile eczema is a predisposing factor 
for asthma (OR 4.33; 95 % confidence interval 3.72–5.01, 
p < 0.0001) [39].
The differences between AD and psoriasis (another 
common cutaneous inflammatory disease) were also 
investigated using meta-analysis of GWAS data [38, 40, 
41]. AD is associated with Type 2—polarized immune 
responses, allergen sensitization and recurrent micro-
bial skin infections, while psoriasis is associated with 
Type 1–polarized immune responses and is not associ-
ated with skin infections. Corresponding to their clinical 
phenotypes, opposing genetic effects were seen on Th2 
locus and loci related to Th1 cytokines and host anti-viral 
genes between AD and psoriasis. Some genetic risk loci 
are in concordance for AD and psoriasis, suggesting that 
these two common dermatological disease share some 
genetic and inflammatory features.
Gene expression profiling assays
Disease related genetic variants usually either alter gene 
expression or change the function of gene products by 
changing protein amino acid structure. Epigenetic modi-
fication and microRNA are important mechanisms that 
can also alter gene expression. Investigation of the tran-
scriptome in disease relevant tissues and cells is there-
fore an ideal strategy to identify molecular signatures 
of complex diseases. Guttman-Yassky et  al. performed 
high-throughput expression profiling on skin biopsies 
from AD lesions compared with health control subjects 
[42]. This study observed that the expression of a large 
number of keratinocyte terminal differentiation genes 
were reduced in AD as compared to normal subjects. The 
affected genes included filaggrin, loricrin (LOR), involu-
crin, late cornified envelope protein LCE2B, S100 fusion 
gene TCHH and multiple S100 family members, etc. This 
study indicated AD was associated with broad defects of 
epidermal cornification in AD skin lesion. These results 
validated a previous microarray profiling study by Sugi-
ura et  al. which revealed down-regulation of LOR and 
FLG in AD skin lesions [43]. More recently, the Gutt-
man-Yassky group used RNA-sequencing technology to 
compare the transcriptomes of nonlesional and lesional 
skin from patients with moderate-to-severe AD. This 
study identified increased expression of a novel TREM-
1 signal pathway as well as IL-36 in AD [44]. Using laser 
capture microdissection to separate epidermis and der-
mis of AD lesional and nonlesional skin compared with 
the expression profiles of normal skin transcriptomes, 
Esaki et al. once again demonstrated that AD lesions had 
down-regulation of genes encoding skin barrier proteins 
including FLG, LOR, CLDN4 and CLDN8; and elevated 
gene expression of Th2 and Th17 cytokines such CCL22, 
CCL26, TSLP and IL-22 etc. [45].
Loss-of-function mutations of the gene encoding 
FLG are the most significant genetic risk factor for AD. 
Cole et  al. conducted a transcriptome profiling study 
using a RNA-sequencing approach to compare non-
lesional skin from AD with site-matched samples from 
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healthy controls [46]. This study found that differentially 
expressed genes between normal and AD subjects were 
enriched in pathways involved in the extracellular space, 
lipid metabolism and stress response. When the whole 
transcriptome data-set was stratified according to FLG 
genotype, FLG deficient skin expressed a type-I inter-
feron-mediated stress response.
A small subset of AD are susceptible to dissemi-
nated herpes simplex virus skin infections, also called 
“eczema herpeticum” (EH). Our lab recently compared 
the transcriptomic changes of peripheral blood mono-
nuclear cells (PBMCs) between AD with a history of EH 
(ADEH+) and AD without a history of AD (ADEH−). 
The results demonstrated that unstimulated ADEH+ and 
ADEH–PBMC had similar transcriptomes. However, fol-
lowing stimulation with herpes simplex virus 1, PBMCs 
from ADEH+  had distinct transcriptome profiles as 
compared to ADEH−, with striking down-regulation 
of anti-viral cytokines including both type I and type 
III interferons. These results are indicative of defective 
innate immune responses in ADEH+ subjects [47].
Epigenetic studies of AD: DNA modification 
and microRNAs (miRNAs)
The prevalence of AD has been increasing too rapidly 
to be accounted for by shifts in genetic variation. These 
changes are thought to be due to environmental factors 
such as industrialization or the western life style associ-
ated with increased stress, more sedentary life style, obe-
sity, low vitamin D level, overuse of antibiotics, etc. [48]. 
Birth cohort studies suggest that both indoor and out-
door pollution are risk factors for the development of AD 
[49]. There is increasing evidence showing that environ-
mental factors regulate gene expression through genomic 
DNA modifications and miRNA mechanisms [50]. A 
study by Liu et al. suggested that diesel exhaust resulted 
in hypermethylation of CpG sites in the IFNG gene pro-
moter and hypomethylation of the IL4 gene promoter. 
This was positively correlated with increased induction of 
IgE in response to intranasal challenge with the allergen, 
Aspergillus fumigatus [51]. This observation is further 
supported by a recent study that poly-aromatic hydro-
carbon such as benzopyrene, derived largely from incom-
plete combustion of organic material, such as fossil fuels, 
coal, wood and tobacco, is associated with increased 
serum IL-4 in children with asthma [52]. Several studies 
demonstrated that Benzo[a]pyrene can decrease global 
DNA methylation by inhibition of DNA methytrans-
ferase expression and interfere with assembling of the 
methylation machinery [53–55]. Another study showed 
that children with prenatal tobacco exposure had a global 
hypomethylation at AluYb8 repeat element in buccal cells 
collected from mouth swab [56].
Several epigenetic studies targeting AD have been con-
ducted and summarized in Table  2. A Chinese group 
led by Lu et  al. have reported that hypomethylation of 
the promoters of TSLP and FCER1G are responsible for 
gene over-expression in AD [57, 58]. A German group 
recently reported an integrated epigenetic and transcrip-
tomic analyses using epidermal lesions from AD patients 
in comparison with healthy control epidermis. The 
results showed that methylation status in AD skin lesions 
was strikingly different from healthy control epidermis 
and was partly correlated with the transcript levels of 
genes involved in epidermal differentiation and immune 
response [59]. In addition, two preliminary studies on 
FLG gene methylation have been reported but gave con-
flicting results [60, 61].
Aside from modification of genomic DNA to tran-
scriptionally regulate gene expression, miRNA mediated 
post-transcriptional regulation is another type of epige-
netic gene expression regulation. miRNAs are a class of 
non-coding molecules that bind to the 3′-UTR of target 
mRNAs and regulate translation [62]. They are highly 
efficient in fine-tuning gene expression, exerting sub-
tle yet significant effects throughout the genome, and 
their expression can be induced by environmental fac-
tors such as microbes and toxins. A few studies have 
Table 2 Epigenetic Studies of AD
Cell/tissue types Epigenetic assay Significant findings Reference
Monocytes FCER1G methylation Demethylation of FCER1G promoter leading to its overexpression in AD. [57]
Skin biopsies TSLP methylation Demethylation of TSLP promoter resulting in its over-expression in AD lesion. [58]
Skin biopsies DNA methylation profiling DNA methylation profiles are striking different in AD skin lesions as compared to 
healthy controls.
[59]
Buccal cells FLG methylation Methylation of the FLG promoter does not affect gene expression and allergy. [60]
Whole blood DNA methylation profiling Methylation of one site cg07548383 in FLG is associated with increased AD risk. [61]
Skin biopsies miRNA profiling Up-regulation of 10 miRNA and down-regulation of 34 miRNAs in AD skin lesions as 
compared to healthy control skins. miR-155 overexpression was validated in T cells 
within skin lesion. Staphylococcal superantigens induce miR-155, it targets CTLA-4.
[63]
Serum and urine miRNA profiling miR-203 and miR-485-5p were significantly up-regulated in serum of AD [65]
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explored whether miRNA are involved in AD pathogen-
esis. The first report by Sonkoly et  al. used PCR-based 
miRNA arrays to compare healthy and AD lesional skin, 
and identified 44 miRNAs that were significantly dif-
ferent between AD and healthy controls with 34 down-
regulated and 10 up-regulated miRNAs. The authors 
further validated miR-155 as significantly over-expressed 
in infiltrating T cells in AD skin lesions [63]. The authors 
found that environmental factors such as dust mite aller-
gen and staphylococcal superantigens could induce miR-
155 expression in atopic skin and identified the immune 
suppressor, CTLA-4, as its target gene [63]. Recently, a 
different group reported that miR-155 could be induced 
by LPS and IL-10 was its target gene [64]. In addition, a 
study conducted in a northern Chinese cohort found that 
miR-203 and miR-483-5p were significantly upregulated 
in serum of children with AD as compared with healthy 
children. The level of miR-483-5p in serum was signifi-
cantly associated with AD and other atopic conditions 
including rhinitis and/or asthma [65].
Discussion
Limitations of current genetic and epigenetic studies 
on AD
Currently, all published studies of gene profiling assays 
with AD have involved relatively small sample sizes. Thus, 
replication and validation are significantly needed. Com-
paring the three different approaches, GWAS assays pro-
vide a relative high degree of replication, suggesting that 
the discovered genetic risk loci are robust. One caveat of 
the existing GWAS studies is that the SNPs identified in 
these studies often have a minor allele frequency greater 
than 1 %; therefore GWAS results cannot fully explain AD 
heritability due to their limited power to detect common 
variants with only a small effect [29]. The “missing herit-
ability” of AD may require identification of rare genetic 
variants using deep sequencing technology such as the 
whole exome sequencing and whole genome sequenc-
ing. Two exome analyses of AD were reported: the study 
by Suzuki et  al. did exome-sequencing on 37 AD with 
the extreme phenotype of serum IgE  >  1000 units. The 
positive hits from this discovery cohort were then vali-
dated in replication cohort including 469 AD and 935 
controls. This approach identified a rare genetic variant 
rs199691576(A/G) in CYP27A1 that is associated with 
AD of high serum total IgE [21]. Another study was per-
formed on 60 Africa American patients with AD and 
found filaggrin-2 variation is associated with a more per-
sistent phenotype [17]. The Atopic Dermatitis Research 
Network (ADRN) funded by National Institute of Health/
National Institute of Allergy and Infectious Diseases 
have initiated whole genome sequencing analyses on AD 
genomes and the results are currently being analyzed [66].
Epigenetic studies of AD are currently at the stage of 
exploratory with small sample sizes investigated. Since 
the epigenetic modifications are tissue-specific and often 
result in gene expression changes, it is the best to investi-
gate epigenetic alteration and gene profiling on the same 
tissue or cells taken from human subjects simultaneously. 
Currently, only one study did so [59].
Based on results of target gene association assays, 
GWAS and transcriptome profiling analyses as well as 
epigenetic studies for AD accomplished so far, genes 
involved in disease pathogenesis mainly fall into two 
pathophysiologic groups: skin barrier genes and immune 
response genes. In most patients, both of these two major 
pathways cross talk with each other to form complex 
pathways leading to the development of AD.
Filaggrin and other skin barrier genes
It is now commonly accepted that skin barrier dysfunc-
tion is an essential feature for the pathogenesis of AD 
[67]. A disrupted skin barrier allows penetration of 
microbes, allergens, toxins and pollutants, leading to 
skin inflammation, allergen sensitization and bacterial 
colonization. Normal epidermal skin barrier function 
requires an intact stratum corneum and tight junctions 
in the stratum granulosum. An earlier linkage study 
for AD had implicated chromosome 1q21 where a very 
large cluster of genes involved in the epidermal differ-
entiation process is located. This group of genes is also 
referred to as “the epidermal differentiation complex 
(EDC)” and includes FLG, loricrin, involucrin, small 
proline-rich proteins (SPRRs), S100A family, S100-fusion 
protein family and late cornified envelope proteins. To 
date, FLG from the EDC cluster is the most significant 
risk factor for AD pathogenesis, and two null muta-
tions R501X and 2282del4 of FLG in Caucasians have 
demonstrated the strongest association for AD (18 and 
48  % of moderate to severe AD, respectively) [68]. Fur-
thermore, the frequency of R501X in AD with a history 
of EH is three times higher (24 vs 8 %, respectively, OR 
11.8 vs 6.2; P = 0.0008) [69] than ADEH− subjects. The 
association of FLG null mutation with AD and EH have 
demonstrated ethnic differences: In Asians, FLG P478 S 
and C3321delA are associated with increased risk to AD, 
the atopic march and recurrent skin infection [70–76]; 
In African populations, FLG mutations are not common 
[77–80]. In contrast to European and Asian AD, loss-of–
function mutations in FLG2, but not FLG, are associated 
with increased risk in African American children [17].
The FLG gene comprises three exons. The third exon 
is the largest and consists of nearly identical tandem 
repeats of about 972 base pair in length and has allelic 
variants of 10, 11 and 12 repeats [81]. A study of an Irish 
case–control cohort found that the number of repeats 
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was significantly lower in AD cases than controls, sug-
gesting that common copy number variations contributes 
to AD risk [82].
Because AD is a complex disease caused by the combi-
nation of genetic variation and environmental factors, it 
is important to evaluate the impact of gene-environment 
interactions. There are two recent articles reported inter-
esting results on the interaction of environmental factors 
and FLG gene mutations [83, 84]. Phthalates are chemi-
cals commonly used in a variety of cosmetic and personal 
care products. Wang et al. recently reported that phtha-
late metabolite levels are significantly associated with 
increased AD risk in Chinese children, and children with 
FLG P478S mutations have increased skin absorption of 
phthalate. These data suggest that FLG mutations may 
increase skin permeability leading to higher skin absorp-
tion of phthalate and thus confer an increased risk for 
AD [84, 85]. Another recent study conducted in Europe 
reported that maternal FLG mutations increase the risk 
of AD in children and this increased risk is independent 
of mutation inheritance, indicating that maternal FLG 
mutations can act as strong environmental risk factors 
for the offspring [83].
There is evidence that additional EDC genes may 
be associated with AD [86]. Recently, a case–control 
study found that a 24-bp deletion in SPRR3 was associ-
ated with AD in European cohorts [87]. However, dele-
tion of LCE3B and LCE3C genes is not associated with 
AD in Caucasians [88]. Although a case–control study 
evaluating polymorphisms across 21 EDC genes in a Ger-
man cohort did not find evidence for associations apart 
from FLG, several transcriptomic profiling studies have 
reported that EDC genes of IVL, LOR and LCE2B, and 
the cell–cell adhesion protein, CDSN, were significantly 
down-regulated in AD skin lesions, suggesting that ele-
vated inflammatory cytokines in the disease loci also play 
an important role for dysregulation of epidermal barrier 
genes [42, 43].
Tight junctions in the granular layer of the epider-
mis play an important role in maintaining skin barrier 
integrity for regulation of transepidermal water loss. 
The claudin family represents one type of tight junction 
transmembrane proteins [89, 90]. The gene expression 
of claudin-1 (CLDN1) has been found to be reduced in 
the AD skin. Both Th2 cytokines and genetic variants 
were responsible for CLDN1 reduction in AD [91, 92]. 
Desmosomes are also important structures to maintain 
skin barrier functions that connect the cell surface to 
the intermediate filament cytoskeleton [93]. Samuelov 
et  al. reported that loss-of-function mutations in gene 
DSG1, which encodes an important desmosome protein 
desmoglein 1, cause severe dermatitis, multiple aller-
gies and metabolic wasting in human [94]. Additionally, 
two groups demonstrated that homozygous mutation 
of TMEM79 is responsible for the spontaneous derma-
titis phenotype in flaky tail mice which was originally 
thought caused solely by FLG mutations [95–97]. Sasaki 
et al. demonstrated that TMEM79 has a function in the 
lamellar granule secretory system [95], indicating that 
this skin barrier deficiency can lead to AD skin inflam-
mation. Moreover, a missense SNP (rs6694514) of human 
TMEM79 was identified to significantly associate with 
AD using a meta-analysis of 4245 AD cases and 10,558 
population-matched control subjects [96]. Several other 
genes including LAMA3 encoding the alpha chain of 
laminin 5, OVOL1 and ACTL9 have been reported to be 
associated with AD [16, 25]. ACTL9 variants, however, 
were not replicated in two independent studies [98, 99].
The serine protease inhibitor of Kazal type 5 (SPINK5) 
gene encoding lympho-epithelial kazal type-related 
inhibitor type 5 (LEKTI) is a crucial protease inhibitor 
for epidermis homeostasis. This gene was found to have 
loss-of-function mutations in Netherton syndrome, a 
severe autosomal recessive skin disease including AD 
and sensitization [100]. Gene variants of SPINK5 was 
found to associate with AD in a Japanese population 
[101]. Functional studies demonstrated that enhanced 
protease activity due to defective function of SPINK5 
led to increased proteolytic activity within the epider-
mis, subsequently resulting in reduced DSG1 and FLG, 
as well as enhanced TSLP expression. These changes all 
contribute to AD pathogenesis [102, 103]. Additionally, 
there is evidence shown that deficient FLG in keratino-
cytes leads to increased IL-1 and TSLP expression [104, 
105]. These studies demonstrate that functional lack 
of epidermal enzyme inhibitors and structural pro-
teins not only compromise the skin barrier integrity, 
but also mediate immunologic responses of allergic 
inflammation.
Adaptive/innate immune response genes
Since AD is associated with allergen sensitization, 
elevated serum IgE and increased expression of Type 
2 cytokines (IL-4, IL5, and IL-13) in both unaffected 
skin and skin lesions of AD, candidate gene studies for 
AD have also focused on the Th2 pathway. Indeed, the 
GWAS assays have repeatedly identified AD genetic risk 
loci around Th2 genes regions at 5q31. Genetic variants 
of genes in the Th2 signaling pathway including IL4, IL13, 
and the IL4 receptor are positively associated with AD 
[10, 106–112]. IL-4 receptor down-stream genes such as 
STAT6 have also been reported to have positive correla-
tions to AD as well [113–115]. Additionally, gene vari-
ants in the alpha and beta chains of the high-affinity IgE 
receptor (FCER1A/B) have been implicated in AD patho-
genesis [116].
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The Th2 cytokine, IL-31, is also increased in AD lesions 
and serum [117–121]. It is not only involved in AD 
inflammatory responses and dysregulation of skin bar-
rier [122–124], but also causes severe itching [125–127]. 
Recently, antibodies against IL-31 receptor A has begun 
to be tested in clinical trials to treat AD and reduced itch-
ing [128]. IL31 polymorphisms have been reported in AD 
by several groups [15, 129, 130].
Both GWAS studies and targeted gene association 
studies have provided evidence for the association of 
AD risk with TSLP gene variants [14, 24]. TSLP can 
be induced in epidermal epithelial cells by a variety of 
stimuli including scratching, viral infections, inflamma-
tory cytokines, protease allergens, bacteria and bacterial 
products [131]. The expression of TSLP is significantly 
increased in AD skin lesions [45]. The major function of 
TSLP is to promote Th2 immune response, thus it has 
been considered to play an important role in AD patho-
genesis. A targeted gene association study reported that 
genetic variants in TSLP are associated with AD, and the 
association is stronger in patients with the ADEH+ phe-
notype [14]. Additionally, polymorphisms of IL-7R 
(T244I at exon 6 and T46I at exon 2), a TSLP receptor, are 
associated with AD [132]. Two other epithelium-derived 
Th2-promoting cytokines IL-33 and IL-25 also play an 
important role in the pathophysiology of AD [133, 134]. 
No genetic polymorphism, however, of these two genes 
has been reported to be associated with AD.
The elevated Type 2 response in AD could be the sec-
ondary effect of impaired Th1 responses or reduced 
inhibitory feedback. Based on this notion, targeted gene 
association studies have also been performed on genes 
in Th1 responses and immune suppression genes. IL12B, 
IL12 receptor beta 1(IL12RB1) and IL-18 promote Th1 
development [135–137]. There are studies reported that 
both IL12B A1188C and IL12RB1 A-111T were associ-
ated with the risk of AD in a Japanese population [138, 
139], and IL18 variants were associated with AD in both 
German and Korean populations [140, 141]. Both sup-
pressor of cytokine signaling 3 (SOCS3) and IL-10 can 
suppress adaptive immune responses [142, 143]. SOCS3 
polymorphism was associated with elevated expression 
in European AD patients [144]; and IL10 (-819 and -592 
promoter polymorphisms) was found to be associated 
with AD in a Korean population [145].
Aside from AD patients prone to EH, AD is often 
complicated by recurrent bacterial infection and other 
types of virus infection. The most common bacterial 
pathogen for AD is Staphylococcus aureus. Mollus-
cum contagiosum virus can cause eczema molluscatum, 
and exposure to vaccinia virus can cause eczema vac-
cinatum after smallpox vaccine inoculation [146]. The 
increased prevalence of skin infections in AD suggest 
that the innate defense system is impaired in AD skin. 
Indeed, genetic variants in multiple genes functioning 
in pattern recognition receptors (PRR) have been impli-
cated in the pathogenesis of AD. A number of genes in 
PRR signaling pathways, including TLR2, TLR9, CD14, 
TOLLIP, MYD88, MAL, NOD1, NOD2 and NALP12, 
has been reported to be associated with AD [147–149]. 
Polymorphisms in anti-microbial peptides of S100 pro-
tein, human defensins α and β and sphingosine have also 
been implicated in AD pathogenesis [147, 148]. In addi-
tion to the direct effect of genetic modifications in innate 
immune response genes, the attenuation of the normal 
antimicrobial response caused by overexpression of Th2 
cytokines in skin is especially relevant in AD. For exam-
ple, it has been demonstrated that Th2 cytokines can 
inhibit gene expression of human β-defensin 3 and LL-37 
in epidermal keratinocytes [150, 151]. Taken together, 
both genetic variation/mutation and acquired impair-
ment of innate immune responses may contribute to Th2 
polarization of AD. However, the genetic loci identified 
by GWAS need further fine mapping in order to identify 
the genes exactly involved; most of the associations men-
tioned by candidate gene assays here involved relatively 
small cohorts, and replication in independent large pop-
ulations are needed. It is critical to note that functional 
validation for these candidate genes represents a signifi-
cant unmet need in the field, and that should be part of 
the future direction in AD research.
Conclusions
In summary, candidate genes for AD suggest that epider-
mal barrier dysfunction, enhanced Th2 immune signal-
ing, weakened innate immune responses, IL-1 signaling 
and the vitamin D pathway etc. have roles in the patho-
genesis of AD. Epigenetic studies also indicate the modi-
fications of genes involved in these pathways as well. The 
dysfunctional epidermal barrier and immune responses 
reciprocally affect each other, and thereby drive the 
development of AD (Fig.  2). Interventions targeting 
either of these pathways can lead to remission of this 
disease.
In the future, it will be important to identify biomark-
ers with prognostic and predictive value for AD. Such 
biomarkers will lead to opportunities for precision medi-
cine in AD. Nevertheless, research accomplishment to 
date further confirmed that FLG mutations and the Type 
2 pathway are major risk factors for AD. Therapeutic rea-
gents improving FLG function and biologics blocking 
Th2 cytokines such as anti-IL-4 receptor alpha, anti-IL-4/
IL-13 or TSLP [152, 153] are evolving as treatment for 
severe AD patients. Based on GWAS studies of the atopic 
march, arrest of AD in infancy may be beneficial for pre-
vention of asthma in this subset of AD patients.
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